{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:28:05Z","timestamp":1783114085947,"version":"3.54.6"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TR003103-01"],"award-info":[{"award-number":["TR003103-01"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TR003103-01"],"award-info":[{"award-number":["TR003103-01"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TR003103-01"],"award-info":[{"award-number":["TR003103-01"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19CSL0134580004"],"award-info":[{"award-number":["19CSL0134580004"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19CSL0134580004"],"award-info":[{"award-number":["19CSL0134580004"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19CSL0134580004"],"award-info":[{"award-number":["19CSL0134580004"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["19CSL0134580004"],"award-info":[{"award-number":["19CSL0134580004"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pauley Heart Center","award":["Pilot Grant"],"award-info":[{"award-number":["Pilot Grant"]}]},{"name":"Pauley Heart Center","award":["Pilot Grant"],"award-info":[{"award-number":["Pilot Grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Sarcoidosis is an inflammatory disease characterized by the formation of granulomas, which involve the heart in up to 25% of patients. Cardiac sarcoidosis can lead to life threatening arrhythmias and heart failure. While corticosteroids have been used as a treatment for over 50\u00a0years, they are associated with hypertension, diabetes, and weight gain, further increasing cardiovascular risk. Interleukin-1 (IL-1) is the prototypical proinflammatory cytokine that works to activate the nuclear transcription factor NF-<jats:italic>k<\/jats:italic>B, one of the targets of glucocorticoids. IL-1 also plays an important role also in the pathophysiology of heart disease including atherosclerosis, myocardial infarction, and myocarditis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Building on a network of research collaborators developed in the Cardiac Sarcoidosis Consortium, we will investigate the feasibility and tolerability of treatment of CS with anakinra at two National Institute of Health Clinical and Translational Science Award (CTSA) hubs with expertise in cardiac sarcoidosis. In this pilot study, up to 28 patients with cardiac sarcoidosis will be recruited to compare the administration of an IL-1 blocker, anakinra, 100\u00a0mg daily on top of standard of care versus standard of care only for 28\u00a0days and followed for 180\u00a0days. Utilizing surrogate endpoints of changes in systemic inflammatory biomarkers and cardiac imaging, we aim to determine whether IL-1 blockade with anakinra can combat systemic and cardiac inflammation in patients with cardiac sarcoidosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The current trial demonstrates an innovative collaborative approach to clinical trial development in a rare, understudied disease that disproportionately affects females and minorities.<\/jats:p><jats:p><jats:italic>Trial Registration<\/jats:italic>The trial was registered prospectively with ClinicalTrials.gov on July 12, 2019, identifier NCT04017936.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12967-021-03130-8","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T17:19:45Z","timestamp":1636391985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART)"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3397-0535","authenticated-orcid":false,"given":"Jordana","family":"Kron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Mihalick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer H.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Koelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzaefah","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamer","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Iden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Polly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Federmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsta","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Lathkar-Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Jasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Birnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Smallfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpha Berry","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Ladd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ellenbogen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Van Tassell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Gregory Hundley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"3130_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/oxfordjournals.aje.a009096","volume":"145","author":"BA Rybicki","year":"1997","unstructured":"Rybicki BA, Major M, Popovich J, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234\u201341.","journal-title":"Am J Epidemiol"},{"key":"3130_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1378\/chest.10-0413","volume":"139","author":"YC Cozier","year":"2011","unstructured":"Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis in black women in the United States: data from the Black Women\u2019s Health Study. Chest. 2011;139:144\u201350.","journal-title":"Chest"},{"key":"3130_CR3","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","volume":"383","author":"D Valeyre","year":"2014","unstructured":"Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, M\u00fcller-Quernheim J. Sarcoidosis. Lancet (London, England). 2014;383:1155\u201367.","journal-title":"Lancet (London, England)"},{"key":"3130_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1183\/09031936.06.00105805","volume":"28","author":"JC Grutters","year":"2006","unstructured":"Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J. 2006;28:627\u201336.","journal-title":"Eur Respir J"},{"key":"3130_CR5","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1164\/ajrccm\/151.3_Pt_1.920a","volume":"151","author":"HL Israel","year":"1995","unstructured":"Israel HL, Gottlieb JE. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med. 1995;151:920\u20131.","journal-title":"Am J Respir Crit Care Med"},{"key":"3130_CR6","first-page":"142","volume":"5","author":"T Izumi","year":"1988","unstructured":"Izumi T. Sarcoidosis in Kyoto (1963\u20131986). Sarcoidosis. 1988;5:142\u20136.","journal-title":"Sarcoidosis"},{"key":"3130_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001114.pub2","author":"NS Paramothayan","year":"2005","unstructured":"Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005. https:\/\/doi.org\/10.1002\/14651858.CD001114.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"3130_CR8","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720\u201332.","journal-title":"Blood"},{"key":"3130_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","volume":"15","author":"S Toldo","year":"2018","unstructured":"Toldo S, Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. 2018;15:203\u201314.","journal-title":"Nat Rev Cardiol"},{"key":"3130_CR10","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1089\/ars.2014.5989","volume":"22","author":"S Toldo","year":"2015","unstructured":"Toldo S, Mezzaroma E, Mauro AG, Salloum F, Van Tassell BW, Abbate A. The inflammasome in myocardial injury and cardiac remodeling. Antioxid Redox Signal. 2015;22:1146\u201361.","journal-title":"Antioxid Redox Signal"},{"key":"3130_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000029536","volume":"67","author":"T Mikuniya","year":"2000","unstructured":"Mikuniya T, Nagai S, Takeuchi M, Mio T, Hoshino Y, Miki H, Shigematsu M, Hamada K, Izumi T. Significance of the interleukin-1 receptor antagonist\/interleukin-1 beta ratio as a prognostic factor in patients with pulmonary sarcoidosis. Respiration. 2000;67:389\u201396.","journal-title":"Respiration"},{"key":"3130_CR12","first-page":"629","volume":"130","author":"K Kasahara","year":"1988","unstructured":"Kasahara K, Kobayashi K, Shikama Y, Yoneya I, Soezima K, Ide H, Takahashi T. Direct evidence for granuloma-inducing activity of interleukin-1. Induction of experimental pulmonary granuloma formation in mice by interleukin-1-coupled beads. Am J Pathol. 1988;130:629\u201338.","journal-title":"Am J Pathol"},{"key":"3130_CR13","doi-asserted-by":"crossref","first-page":"e007582","DOI":"10.1161\/CIRCEP.119.007582","volume":"12","author":"J Kron","year":"2019","unstructured":"Kron J, Mauro AG, Bonaventura A, Toldo S, Salloum FN, Ellenbogen KA, Abbate A. Inflammasome formation in granulomas in cardiac sarcoidosis. Circul Arrhythmia Electrophysiol. 2019;12:e007582.","journal-title":"Circul Arrhythmia Electrophysiol"},{"key":"3130_CR14","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","volume":"70","author":"P Libby","year":"2017","unstructured":"Libby P. Interleukin-1 beta as a target for atherosclerosis therapy: Biological basis of CANTOS and beyond. J Am Coll Cardiol. 2017;70:2278\u201389.","journal-title":"J Am Coll Cardiol"},{"key":"3130_CR15","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1093\/eurheartj\/ehy128","volume":"39","author":"LF Buckley","year":"2018","unstructured":"Buckley LF, Abbate A. Interleukin-1 blockade in cardiovascular diseases: a clinical update. Eur Heart J. 2018;39:2063\u20139.","journal-title":"Eur Heart J"},{"key":"3130_CR16","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","volume":"11","author":"DH Birnie","year":"2014","unstructured":"Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305\u201323.","journal-title":"Heart Rhythm"},{"key":"3130_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.17996\/anc.17-00042","volume":"3","author":"FYK Terasaki","year":"2017","unstructured":"Terasaki FYK. New guidelines for diagnosis of cardiac sarcoidosis in Japan. An Nucl Cardiol. 2017;3:42\u20135.","journal-title":"An Nucl Cardiol"},{"key":"3130_CR18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1164\/rccm.201410-1785OC","volume":"191","author":"MA Judson","year":"2015","unstructured":"Judson MA, Mack M, Beaumont JL, Watt R, Barnathan ES, Victorson DE. Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure. Am J Respir Crit Care Med. 2015;191:786\u201395.","journal-title":"Am J Respir Crit Care Med"},{"key":"3130_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809798","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ. Low-Dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/NEJMoa1809798.","journal-title":"N Engl J Med"},{"key":"3130_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cardfail.2020.08.013","volume":"27","author":"NA Gilotra","year":"2021","unstructured":"Gilotra NA, Wand AL, Pillarisetty A, Devraj M, Pavlovic N, Ahmed S, Saad E, Solnes L, Garcia C, Okada DR, Constantinescu F, Mohammed SF, Griffin JM, Kasper EK, Chen ES, Sheikh FH. Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience. J Cardiac Fail. 2021;27:83\u201391.","journal-title":"J Cardiac Fail"},{"key":"3130_CR21","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133\u201340.","journal-title":"Circulation"},{"key":"3130_CR22","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275\u201385.","journal-title":"JAMA"},{"key":"3130_CR23","doi-asserted-by":"publisher","first-page":"vii5","DOI":"10.1093\/rheumatology\/key059","volume":"57","author":"R Caporali","year":"2018","unstructured":"Caporali R, Crepaldi G, Codullo V, Benaglio F, Monti S, Todoerti M, Montecucco C. 20 years of experience with tumour necrosis factor inhibitors: what have we learned? Rheumatology (Oxford). 2018;57:vii5\u201310.","journal-title":"Rheumatology (Oxford)"},{"key":"3130_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.amjcard.2014.11.003","volume":"115","author":"A Abbate","year":"2015","unstructured":"Abbate A, Kontos MC, Abouzaki NA, Melchior RD, Thomas C, Van Tassell BW, Oddi C, Carbone S, Trankle CR, Roberts CS, Mueller GH, Gambill ML, Christopher S, Markley R, Vetrovec GW, Dinarello CA, Biondi-Zoccai G. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol. 2015;115:288\u201392.","journal-title":"Am J Cardiol"},{"key":"3130_CR25","doi-asserted-by":"publisher","first-page":"e33438","DOI":"10.1371\/journal.pone.0033438","volume":"7","author":"BW Van Tassell","year":"2012","unstructured":"Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, Shah K, Canada J, Voelkel NF, Dinarello CA, Abbate A. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS ONE. 2012;7:e33438.","journal-title":"PLoS ONE"},{"key":"3130_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","author":"BW Van Tassell","year":"2017","unstructured":"Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C, Abouzaki NA, Dixon D, Kadariya D, Christopher S, Schatz A, Regan J, Viscusi M, Del Buono M, Melchior R, Mankad P, Lu J, Sculthorpe R, Biondi-Zoccai G, Lesnefsky E, Arena R, Abbate A. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail. 2017. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004373.","journal-title":"Circ Heart Fail"},{"key":"3130_CR27","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, Group CT. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331.","journal-title":"N Engl J Med"},{"key":"3130_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038010","author":"BM Everett","year":"2018","unstructured":"Everett BM, Cornel J, Lainscak M, Anker SD, Abbate A, Thuren T, Libby P, Glynn RJ, Ridker PM. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2018. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038010.","journal-title":"Circulation"},{"key":"3130_CR29","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1017\/cts.2021.777","volume":"5","author":"YR Sedhai","year":"2021","unstructured":"Sedhai YR, Sears M, Vecchi\u00e8 A, Bonaventura A, Greer J, Spence K, Tackett H, Turner J, Pak M, Patel N, Black M, Wohlford G, Clary RE, Duke C, Hardin M, Kemp H, Priday A, Sims EK, Mihalick V, Ho AC, Ibe I, Harmon M, Markley R, Van Tassell B, Abbate A. Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic. J Clin Transl Sci. 2021;5:e136.","journal-title":"J Clin Transl Sci"},{"key":"3130_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet (London, England). 2018;391:319\u201328.","journal-title":"Lancet (London, England)"},{"key":"3130_CR31","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","volume":"113","author":"BW Van Tassell","year":"2014","unstructured":"Van Tassell BW, Arena R, Biondi-Zoccai G, Canada JM, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014;113:321\u20137.","journal-title":"Am J Cardiol"},{"key":"3130_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ejhf.1403","volume":"21","author":"LF Buckley","year":"2019","unstructured":"Buckley LF, Canada JM, Carbone S, Trankle CR, Kadariya D, Billingsley H, Wohlford GF, Kirkman DL, Abbate A, Van Tassell BW. Potential role for interleukin-1 in the cardio-renal syndrome. Eur J Heart Fail. 2019;21:385\u20136.","journal-title":"Eur J Heart Fail"},{"key":"3130_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jacc.2013.09.022","volume":"63","author":"R Blankstein","year":"2014","unstructured":"Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, Kazemian P, Kwong RY, Tokuda M, Skali H, Padera R, Hainer J, Stevenson WG, Dorbala S, Di Carli MF. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"3130_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2967\/jnumed.112.115121","volume":"55","author":"I Schatka","year":"2014","unstructured":"Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med. 2014;55:99\u2013106.","journal-title":"J Nucl Med"},{"key":"3130_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1161\/CIRCIMAGING.111.967836","volume":"5","author":"P Thavendiranathan","year":"2012","unstructured":"Thavendiranathan P, Walls M, Giri S, Verhaert D, Rajagopalan S, Moore S, Simonetti OP, Raman SV. Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 mapping. Circ Cardiovasc Imaging. 2012;5:102\u201310.","journal-title":"Circ Cardiovasc Imaging"},{"key":"3130_CR36","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.jacc.2005.01.047","volume":"45","author":"JP Smedema","year":"2005","unstructured":"Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, Crijns HJ. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"3130_CR37","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1161\/CIRCULATIONAHA.109.851352","volume":"120","author":"MR Patel","year":"2009","unstructured":"Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969\u201377.","journal-title":"Circulation"},{"key":"3130_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1148\/rg.291085052","volume":"29","author":"KW Cummings","year":"2009","unstructured":"Cummings KW, Bhalla S, Javidan-Nejad C, Bierhals AJ, Gutierrez FR, Woodard PK. A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging. Radiographics. 2009;29:89\u2013103.","journal-title":"Radiographics"},{"key":"3130_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jcmg.2016.05.009","volume":"10","author":"GC Coleman","year":"2017","unstructured":"Coleman GC, Shaw PW, Balfour PC Jr, Gonzalez JA, Kramer CM, Patel AR, Salerno M. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging. 2017;10:411\u201320.","journal-title":"JACC Cardiovasc Imaging"},{"key":"3130_CR40","doi-asserted-by":"publisher","DOI":"10.23736\/S00264806.21.07566-2","author":"WJ Moeller","year":"2021","unstructured":"Moeller WJ, Potere N, Bonaventura A, Vecchi\u00e8 A, Sedhai YR, Caricchio R, Abbate A. Use of placebo in clinical trials in COVID-19 pandemic times: considerations on pros, cons, challenges and limitations. Minerva Med. 2021. https:\/\/doi.org\/10.23736\/S00264806.21.07566-2 (Epub ahead of print).","journal-title":"Minerva Med"},{"key":"3130_CR41","doi-asserted-by":"crossref","first-page":"e015594","DOI":"10.1161\/JAHA.119.015594","volume":"9","author":"MS Khan","year":"2020","unstructured":"Khan MS, Shahid I, Siddiqi TJ, Khan SU, Warraich HJ, Greene SJ, Butler J, Michos ED. Ten-year trends in enrollment of women and minorities in pivotal trials supporting recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs. J Am Heart Assoc. 2020;9:e015594.","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-03130-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-021-03130-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-03130-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T18:10:13Z","timestamp":1673719813000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-021-03130-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3130"],"URL":"https:\/\/doi.org\/10.1186\/s12967-021-03130-8","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was obtained from VCU and University of Michigan prior to the start of the trial, with University of Michigan relying on the VCU IRB. IRB HM20015843; Initial approval date: 8\/5\/2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Abbate (AA) has served as consultant to Swedish Orphan Biovitrum in the past. Dr. Van Tassell (BVT) has served as consultant to Swedish Orphan Biovitrum in the past. No other authors have relevant disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"460"}}